Beta Bionics, Inc.'s Lock-Up Period Will Expire on July 29th (NASDAQ:BBNX)

Beta Bionics' (NASDAQ:BBNX - Get Free Report) lock-up period will expire on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its public offering on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. The Goldman Sachs Group assumed coverage on Beta Bionics in a research report on Friday, May 30th. They issued a "neutral" rating and a $16.00 price target for the company. Wolfe Research started coverage on Beta Bionics in a research report on Friday, May 30th. They set an "outperform" rating and a $20.00 target price on the stock. Lake Street Capital started coverage on Beta Bionics in a research report on Thursday, June 12th. They set a "buy" rating and a $30.00 target price on the stock. Finally, Truist Financial started coverage on Beta Bionics in a research report on Monday, June 16th. They set a "buy" rating and a $26.00 target price on the stock. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $23.44.

Beta Bionics Stock Performance

Shares of NASDAQ:BBNX opened at $14.30 on Tuesday. The company's fifty day moving average is $15.61. Beta Bionics has a one year low of $8.89 and a one year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Insiders Place Their Bets

In other Beta Bionics news, CFO Stephen Feider sold 1,497 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $26,781.33. Following the completion of the sale, the chief financial officer directly owned 45,503 shares in the company, valued at $814,048.67. This represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 4,519 shares of company stock valued at $80,845 in the last three months.

Institutional Trading of Beta Bionics

Several hedge funds and other institutional investors have recently modified their holdings of BBNX. Palumbo Wealth Management LLC acquired a new position in Beta Bionics during the second quarter worth $431,000. Goldman Sachs Group Inc. acquired a new position in Beta Bionics during the first quarter worth $715,000. Rhumbline Advisers acquired a new position in Beta Bionics during the first quarter worth $158,000. Strs Ohio acquired a new position in Beta Bionics during the first quarter worth $29,000. Finally, Woodline Partners LP acquired a new position in Beta Bionics during the first quarter worth $1,530,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.